BioSpace News Archive

YDS Pharmatech today announced the appointment of Dr. Robert Sullivan as Head of Medicinal Chemistry.

Totus Medicines announced today the dosing of the first patient in a Phase 1 clinical trial of TOS-358, the company’s first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.

Ventus Therapeutics, Inc. announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference, being held April 25-26 in Toronto.

Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, May 4, 2023, at 8:00 a.m. ET to report its first quarter 2023 financial results and other business highlights.

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023.

During the National Kidney Foundation’s (NKF) Spring Clinical Meetings in Austin, TX from April 11-15, 2023, Massachusetts General Hospital (MGH), researchers will present new data highlighting long-term outcomes for cynomolgus macaques transplanted with kidney xenografts from porcine donors harboring genetic modifications.

Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS).

Affini-T Therapeutics and Christopher A. Klebanoff, M.D., recently appointed Scientific Co-founder and Advisor for Affini-T Therapeutics, to present on KRAS G12D specific T cell receptors.

BioAegis Therapeutics, Inc. announces publication of two new research studies exploring gelsolin’s role in type 2 diabetes, an inflammation-related metabolic disease.